GLP-1 receptor agonists in obesity-related knee osteoarthritis: from weight loss to therapeutic pathway reconstruction
Frontiers in Pharmacology · 17.06.2026 · 17
DOI: 10.3389/fphar.2026.1856307 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 17.06.2026. Verfasst von Jincan Wu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Massage Therapy, Xiamen Hospital of Traditional Chinese Medicine, Xiamen, China. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Obesity is a major modifiable contributor to knee osteoarthritis (KOA), but excess adiposity has often been managed as a background risk factor rather than as a therapeutic target. In obesity-related KOA, adiposity may aggravate pain and disability through increased joint loading, low-grade inflammation, metabolic dysfunction, impaired physical activity, and reduced rehabilitation tolerance. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have created a new opportunity to achieve clinically meaningful weight loss in selected patients with obesity-related KOA. However, current evidence should be interpreted cautiously. Human data most strongly support weight-loss-mediated improvements in pain, function, and rehabilitation feasibility, whereas direct cartilage-, synovium-, subchondral bone-, or structure-modifying effects remain unproven. In this narrative review, we summarize the rationale, receptor biology, pharmacological mechanisms, inflammatory signaling hypotheses, clinical evidence, safety concerns, and implementation challenges related to GLP-1RA use in obesity-related KOA. We also position GLP-1RAs within a broader obesity-treatment continuum that includes lifestyle intervention, exercise-based rehabilitation, multidisciplinary weight management, other anti-obesity medications, bariatric surgery, symptom-bridging treatments, and arthroplasty when indicated. Particular attention is given to gastrointestinal intolerance, dehydration, gallbladder and pancreatitis-related concerns, lean-mass loss, perioperative management, treatment discontinuation, affordability, access, and long-term adherence. Overall, GLP-1RAs may become a useful component of integrated obesity-directed KOA care, but they should be regarded as part of a proposed framework rather than as validated disease-modifying therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Massage Therapy, Xiamen Hospital of Traditional Chinese Medicine, Xiamen, China.
- Department of Acupuncture, Sanya Hospital of Traditional Chinese Medicine, Sanya, China.
Zitieren
APA
Wu, J., Lei, Y., Sa, R., Zhong, Y., & Lu, Y. (2026). GLP-1 receptor agonists in obesity-related knee osteoarthritis: from weight loss to therapeutic pathway reconstruction. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1856307
Vancouver
Wu J, Lei Y, Sa R, Zhong Y, Lu Y. GLP-1 receptor agonists in obesity-related knee osteoarthritis: from weight loss to therapeutic pathway reconstruction. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1856307
BibTeX
@article{Wu2026,
author = {Wu, Jincan and Lei, Ying and Sa, Ren and Zhong, Yongquan and Lu, Yunqiong},
title = {GLP-1 receptor agonists in obesity-related knee osteoarthritis: from weight loss to therapeutic pathway reconstruction},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {17},
doi = {10.3389/fphar.2026.1856307}
}
EUVIMED